Mobile Lung Cancer Screening (MobILYAD)

Civil Hospices of Lyon

Status: Enrolling

Conditions: Lung Cancer Prevention

Treatments: Behavioral: Smoking Cessation Support; Diagnostic Test: Low-dose Chest CT Screening; Diagnostic Test: Cardiovascular Risk Assessment; Diagnostic Test: Spirometry; Other: Optional Biospecimen Collection (Bio-ILYAD)

Study type: Observational

Funder types: Other

Identifiers

NCT07015151

2025-A00673-46 (Other Identifier)

69HCL22_0467

Details and patient eligibility

About

Lung cancer screening using low-dose CT (LDCT) has been shown to reduce mortality in high-risk populations. In 2022, the French National Cancer Institute (INCa) issued guidelines recommending screening for individuals aged 50-74 with a history of heavy smoking, including current smokers or those who quit less than 15 years ago. A national pilot program (IMPULSION) will be launched in 2025.

Lung cancer incidence is strongly correlated with socioeconomic status, yet underserved populations remain difficult to engage in screening programs. Mobile health units using a "reach-out" strategy have demonstrated effectiveness in other countries (UK, Brazil, USA). In France, this approach has been used for breast cancer screening via mobile mammography units.

The MobILYAD project aims to compare two screening modalities- a mobile demedicalized unit (CT-equipped van with trained nurses) and a conventional hospital-based unit- to assess the effectiveness of mobile screening in reaching socially disadvantaged populations.

Enrollment: 4,312 estimated patients

Sex: All

Ages: 50 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria * :

• Persons aged over 50 and under 75 (74 years of age or older).

• Active smokers or former smokers who quit less than 15 years ago.

• Persons whose consumption is estimated at 20 packs/year or more, down to ≥15 cigarettes/day for a duration of consumption of ≥25 years and up to ≥10 cigarettes/day for ≥30 years, which takes into account the predominance of duration of consumption over quantity consumed in the risk of lung cancer. A pack-year corresponds to the consumption of one pack of 20 manufactured cigarettes per day for one year. A multiplier coefficient will be taken into account depending on the mode of consumption: Rolled cigarettes: 2; Cigarillos: 3; Cigars: 4; Pipes: 2.5; Hookahs: 25.

• Persons affiliated with social security. - Person having signed their consent to participate in the study after having received full information about it, including the risks associated with participation.

  • Exclusion Criteria * :

• Individuals with severe comorbidities contraindicating lung cancer investigations and/or treatment (including surgery or stereotactic radiotherapy);

• Individuals with impaired general condition (PS 2 and above);

• Individuals with dyspnea at rest (mMRC4);

• Individuals with a history of cancer undergoing active surveillance by chest computed tomography (CT or PET scan); personal history of lung cancer (lifetime);

• Individuals with symptoms suggestive of lung cancer (hemoptysis, unexplained weight loss, recent onset or change in respiratory symptoms, etc.);

• Individuals refusing to participate in the study

• Individuals withdrawing their consent.

Trial design

4,312 participants in 2 patient groups

Mobile Screening Group

Description:

Participants receiving lung cancer screening via a mobile unit (truck) operated by trained nurses. This includes spirometry, blood pressure measurement, blood cholesterol testing, low-dose CT scan, and optional biospecimen collection.

Treatment:

Other: Optional Biospecimen Collection (Bio-ILYAD)

Diagnostic Test: Cardiovascular Risk Assessment

Diagnostic Test: Spirometry

Diagnostic Test: Low-dose Chest CT Screening

Behavioral: Smoking Cessation Support

Non-Mobile Screening Group

Description:

Participants receiving the same screening procedures at a fixed hospital-based site (Lyon Sud), with possible involvement of medical or non-medical staff depending on availability.

Treatment:

Other: Optional Biospecimen Collection (Bio-ILYAD)

Diagnostic Test: Cardiovascular Risk Assessment

Diagnostic Test: Spirometry

Diagnostic Test: Low-dose Chest CT Screening

Behavioral: Smoking Cessation Support